ATyr Pharma (ATYR) said Wednesday it has advanced ATYR0101 to the investigational new drug candidate stage to potentially treat pulmonary fibrosis.
Chief Executive Sanjay S. Shukla said they anticipate filing an IND application in H2 of 2026.
The company said preclinical data showed ATYR0101 can induce cell death of myofibroblasts through interaction with LTBP-1. Myofibroblasts are the cells that drive progression of fibrosis.
Shares of the company were down 1.2% in early trading Wednesday.
Price: 3.27, Change: -0.04, Percent Change: -1.21
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.